作 者丨 见习记者李益文 编 辑丨陈思颖 尹华禄 黎雨桐 4月8日下午，据央视新闻消息，国务院国资委8日表示， 将全力支持推动中央企业及其控股上市公司主动作为，不断加大增持回购力度，切实 维护全体股东权益，持续巩固市场对上市公司的信心，努力提升公司价值，充分彰显央企责任担当。 同时，加大对央企市值管理工作的指导， 引导中央企业持续为投资者打造负责任、有实绩、可持续、守规矩的价值投资优质标的，为促进资本市场健康稳定发展作出贡献。 此前，A股市场回购与增持热潮已持续升温。截至8日1 3时3 0分左右， 当日已有近3 0家公司宣布加入股票增持回购行列，涉及金额最高超3 0 0 亿元。 继宁德时代（3 0 0 7 5 0 .SZ）、中国核电（6 0 1 9 8 5 .SH）之后，贵州茅台( 6 0 0 5 1 9 .SH)、招商蛇口( 0 0 1 9 7 9 .SZ)、荣盛石化（0 0 2 4 9 3 .SZ）等一 众龙头企业也相继公布了新一轮回购及增持计划。据Wi n d数据不完全统计，从4月7日盘后到截至目前，总共有7 0余家公司发布了回购公告， 2 0余家公司发布了增持公告。与此同时，"国家队"也同步表态加码， ...

蓝思科技：拟以5亿元-10亿元回购公司股份，用于实施员工持股计划或股权激励计划。回购 股份价格上限35元/股。 4月8日盘前，"国家队"果断出手之际，A股上市公司也掀起回购潮，用行动表信心，为市场注入稳定信 号。 招商局集团旗下7家上市公司计划提速实施股份回购计划，贵州茅台已着手起草新一轮回购股份方案， 国泰君安、美的集团、复星医药、京东方Ａ、蓝思科技等也纷纷加入回购： 招商局集团旗下7家上市公司招商蛇口、招商港口、招商轮船、招商公路、中国外运、辽港 股份、招商积余集体发布公告，基于对公司未来发展前景的坚定信心及内在价值的高度认 可，计划提速实施股份回购计划，切实维护上市公司全体股东权益，持续巩固市场对上市公 司的信心，提升上市公司投资价值。 贵州茅台：公司已着手起草新一轮回购股份方案，公司控股股东已着手起草增持方案。据公 告，截至2025年4月7日，贵州茅台已累计回购股份1,315,901股，占公司总股本的比例为 0.1048%，购买的最高价为1,584.06元/股、最低价为1,417.01元/股，已支付的总金额为 1,948,495,151.53元（不含交易费用）。上述回购进展符合法律法规的规定及公司披露 ...

国泰君安公告，公司董事长朱健于2025年4月7日提议，公司通过集中竞价交易方式回购部分公司A股股 份，回购股份将用于维护公司价值及股东权益。回购股份种类为人民币普通股(A股)股票，价格上限不 高于董事会审议通过回购股份方案决议前30个交易日公司股票交易均价的150%，资金总额为10亿元-20 亿元，资金来源为公司自有资金，回购期限为自董事会审议通过方案之日起3个月内。 东方证券：拟以2.5亿元-5亿元回购股份 A股市场剧烈波动关键时刻，上市公司回购潮再起！据不完全统计，从昨日收盘到今晨，A股超20家上 市公司发布回购计划或提速回购计划。 "招商系"7家上市公司：坚定信心提速回购 招商局集团旗下7家上市公司招商蛇口（001979）、招商港口（001872）、招商轮船（601872）、招商 公路（001965）、中国外运（601598）、辽港股份（601880）、招商积余（001914），4月8日盘前集体 发布公告，基于对公司未来发展前景的坚定信心及内在价值的高度认可，计划提速实施股份回购计划， 切实维护上市公司全体股东权益，持续巩固市场对上市公司的信心，提升上市公司投资价值。 国泰君安：董事长提议以10亿元-2 ...

证券代码：600958 证券简称：东方证券 公告编号：2025-016 东方证券股份有限公司 关于筹划回购公司 A 股股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 东方证券股份有限公司（以下简称"公司"）坚定看好中国资本 市场发展前景，积极维护公司价值及股东权益，目前正在筹划回购公 司股份事项，具体情况如下： 一、拟回购股份的种类 公司发行的人民币普通股（A 股）股票。 二、拟回购股份的用途 公司自有资金。 四、拟回购股份的方式、资金总额及回购价格 公司拟通过集中竞价交易方式回购股份，回购资金额预计为 2.5-5 亿元人民币。本次回购股份按法律法规允许的价格进行。 五、实施期限 本次回购股份实施期限将在符合所有适用的法律、法规及公司股 票上市地证券监督管理机构的相关规则的前提下进行。 六、风险提示 目前该事项正在筹划之中，公司将尽快制定合理可行的回购股份 方案，并按照相关规定履行审批程序并及时履行信息披露义务。审议 通过后的最终方案可能与本次公告内容存在差异，请以经公司履行审 1 批程序后最终审议通过的方案 ...

Quantitative Models and Factor Analysis Quantitative Factors and Construction Methods - **Factor Name**: Non-liquidity Shock **Construction Idea**: Measures the impact of illiquidity on stock returns **Construction Process**: Calculated as the average absolute daily return over the past 20 trading days divided by the corresponding daily trading volume[6][16][19] **Evaluation**: Demonstrated strong performance across multiple indices, indicating its effectiveness in capturing illiquidity effects[6][19][21] - **Factor Name**: Six-Month UMR **Construction Idea**: Captures momentum adjusted for risk over a six-month window **Construction Process**: Risk-adjusted momentum is calculated using a six-month rolling window, incorporating volatility adjustments[6][16][19] **Evaluation**: Consistently performed well in recent periods, showing robustness across different market conditions[6][19][21] - **Factor Name**: One-Year UMR **Construction Idea**: Similar to Six-Month UMR but uses a one-year window for risk-adjusted momentum **Construction Process**: Momentum is adjusted for risk using a one-year rolling window, factoring in volatility[6][16][19] **Evaluation**: Effective in capturing long-term momentum trends, though performance varies by index[6][19][21] - **Factor Name**: Three-Month Volatility **Construction Idea**: Measures short-term price fluctuations **Construction Process**: Calculated as the standard deviation of daily returns over the past 60 trading days[6][16][19] **Evaluation**: Demonstrated strong negative correlation with returns, indicating its utility in identifying high-risk assets[6][19][21] - **Factor Name**: One-Month Turnover **Construction Idea**: Reflects trading activity and liquidity over a short period **Construction Process**: Average daily turnover rate over the past 20 trading days[6][16][19] **Evaluation**: Effective in capturing liquidity dynamics, though performance varies across indices[6][19][21] Factor Backtesting Results - **Non-liquidity Shock**: - Recent Week: 0.58% (HS300), 0.91% (CSI500), 0.93% (CSI800), 0.87% (CSI1000), 1.14% (CSI All)[19][23][27][31][42] - Recent Month: 0.31% (HS300), 0.64% (CSI500), 0.77% (CSI800), 2.40% (CSI1000), 1.33% (CSI All)[19][23][27][31][42] - **Six-Month UMR**: - Recent Week: 0.54% (HS300), -0.09% (CSI500), 0.57% (CSI800), 0.73% (CSI1000), 0.73% (CSI All)[19][23][27][31][42] - Recent Month: 1.53% (HS300), 2.09% (CSI500), 2.35% (CSI800), 3.49% (CSI1000), 3.85% (CSI All)[19][23][27][31][42] - **One-Year UMR**: - Recent Week: 0.46% (HS300), 0.06% (CSI500), 0.88% (CSI800), 0.52% (CSI1000), 0.76% (CSI All)[19][23][27][31][42] - Recent Month: 1.15% (HS300), 2.19% (CSI500), 2.50% (CSI800), 2.85% (CSI1000), 3.74% (CSI All)[19][23][27][31][42] - **Three-Month Volatility**: - Recent Week: 0.24% (HS300), 0.78% (CSI500), 0.59% (CSI800), 0.65% (CSI1000), 0.86% (CSI All)[19][23][27][31][42] - Recent Month: 0.84% (HS300), 3.24% (CSI500), 2.17% (CSI800), 3.63% (CSI1000), 3.60% (CSI All)[19][23][27][31][42] - **One-Month Turnover**: - Recent Week: -0.05% (HS300), 0.48% (CSI500), 0.04% (CSI800), 0.57% (CSI1000), 0.50% (CSI All)[19][23][27][31][42] - Recent Month: 0.19% (HS300), 2.47% (CSI500), 0.19% (CSI800), 3.87% (CSI1000), 1.65% (CSI All)[19][23][27][31][42] Quantitative Model Construction - **Model Name**: Maximized Factor Exposure Portfolio (MFE) **Construction Idea**: Optimizes portfolio weights to maximize exposure to a single factor while controlling for constraints **Construction Process**: - Objective Function: Maximize $f^T w$, where $f$ is the factor value and $w$ is the weight vector - Constraints: Include style exposure, industry deviation, stock weight limits, turnover, and full investment constraints - Formula: $\begin{array}{ll}max&f^{T}w\\ s.t.&s_{l}\leq X(w-w_{b})\leq s_{h}\\ &h_{l}\leq H(w-w_{b})\leq h_{h}\\ &w_{l}\leq w-w_{b}\leq w_{h}\\ &b_{l}\leq B_{b}w\leq b_{h}\\ &0\leq w\leq l\\ &1^{T}w=1\\ &\Sigma|w-w_{0}|\leq to_{h}\end{array}$[57][58][61] **Evaluation**: Provides a robust framework for testing factor effectiveness under realistic constraints[57][58][61] Model Backtesting Results - **MFE Portfolio**: - Demonstrated strong performance in capturing factor-specific returns while adhering to constraints such as turnover and industry exposure[57][58][61]

Core Viewpoint - The article discusses the significant decline in brokerage commission income from fund distribution in 2024, primarily due to the reform of public fund commission rates and a decrease in trading volume [3][4][9]. Summary by Sections Fund Distribution Commission Income - In 2024, the total commission income from fund distribution for brokerages was 10.652 billion yuan, a decrease of 35% compared to 16.466 billion yuan in 2023, marking a third consecutive year of decline [3]. - The decline in commission income is attributed to two main factors: a decrease in public fund stock trading volume, which was 20.51 trillion yuan in 2024, down approximately 8% from 22.34 trillion yuan in 2023, and a significant reduction in commission rates from 0.0737% in 2023 to approximately 0.0519% in 2024 [3][4]. Performance of Major Brokerages - Among large and medium-sized brokerages, Huatai Securities, GF Securities, and Zheshang Securities experienced smaller declines in commission income, ranging from 17% to 24%, while Everbright Securities and Galaxy Securities saw declines exceeding 50% [4]. - The ranking of the top ten brokerages by fund distribution commission income in 2024 included CITIC Securities, GF Securities, and Changjiang Securities, with some brokerages like Zheshang Securities improving their rankings [6][7]. Changes in Brokerage Rankings - CITIC Securities, GF Securities, and Xingye Securities maintained their rankings from 2023, while Zheshang Securities improved by six positions. Conversely,招商证券 and中信建投证券 dropped in rankings due to significant declines in their commission income, with decreases of 46.59% and 37.35%, respectively [8][10]. Impact of Regulatory Changes - The new regulations separating fund sales from public trading commissions have shifted the focus towards research value, leading to a more pronounced differentiation in income among brokerages [9][14]. - The concentration of commission income remains high, with the top 30 brokerages accounting for approximately 87% of total commission income, indicating challenges for smaller brokerages to capture market share [14]. Strategies for Adaptation - Brokerages are exploring diverse development paths to counteract declining commission income, including enhancing wealth management services, expanding overseas client bases, and creating integrated research systems [17][18][19]. - Specific strategies include leveraging research to support wealth management, developing international service platforms, and optimizing research resources to enhance service levels for core clients [18][19].

Core Viewpoint - The Shanghai Stock Exchange's listing review committee approved the initial public offering (IPO) of Jiyuan Group Co., Ltd., marking it as the ninth company to pass the review this year [1] Company Overview - Jiyuan Group is an international enterprise group specializing in the research, innovation, and industrialization of dietary nutritional supplements [1] - As of the signing date of the prospectus, Jiyuan (Hong Kong) Limited holds 27,567.38 million shares, accounting for 78.76% of Jiyuan Group's total share capital, making it the controlling shareholder [1] Shareholding Structure - Zhou Jingshi and Long Ling hold 58.91% and 62.82% of TSI Group Limited and TSI Holdings International Inc., respectively, which in turn hold 90.91% and 9.09% of Jiyuan Hong Kong [2] - The couple controls 84.47% of the voting rights of Jiyuan Group through Jiyuan Hong Kong and Jiyuan Consulting [2] IPO Details - Jiyuan Group plans to publicly issue no less than 50.01 million shares, representing at least 10% of the total share capital post-issuance [3] - The company aims to raise 602.73 million yuan for projects including the construction of a nutritional health raw material production base and the expansion of a nutritional health food production line [3] Key Questions from Listing Committee - The committee inquired about the company's operational environment, potential significant changes, and risks of substantial performance decline [4] - Questions were raised regarding the company's reliance on Abbott Group, including the history of cooperation, contract terms, and pricing stability [4]

Core Viewpoint - The Shanghai Stock Exchange has approved the IPO of Jiyuan Group, a company specializing in the research and development of dietary nutritional supplements, marking a significant step in its growth and expansion in the global market [1]. Company Overview - Jiyuan Group is an international enterprise focused on the R&D and industrialization of dietary nutritional supplements, providing innovative and customized nutritional raw materials and formulations [2]. - The company is the largest global supplier of HMB (beta-hydroxy-beta-methylbutyrate) and a core supplier of high-quality glucosamine and other products, with a strong market presence across major regions including China, Asia, the US, Europe, Australia, and South America [2][9]. Financial Performance - The company reported revenues of 947 million yuan, 892 million yuan, and 1.002 billion yuan for the years 2022, 2023, and 2024, respectively, with net profits of 143 million yuan, 153 million yuan, and 171 million yuan during the same period [4]. - As of December 31, 2024, total assets amounted to 1.186 billion yuan, with a debt-to-asset ratio of 20.23% [5]. - The company anticipates a revenue growth of approximately 14.39% year-on-year for Q1 2025, with net profit expected to increase by about 6.42% to 11.55% [5]. Market Position - Jiyuan Group holds a market share of approximately 65.80% in the global HMB market, with projected shares of 52.27% and 53.34% for 2023 and 2024, respectively [9]. - The company has established a solid position in the glucosamine market, with market shares of 11.92%, 13.85%, and 12.61% from 2022 to 2024 [10]. Client Relationships - The company heavily relies on Abbott Group, with sales to Abbott accounting for 23.44%, 17.38%, and 19.44% of its main business revenue over the reporting periods, and 69.26%, 64.69%, and 66.19% of its HMB business revenue [11]. - Over 90% of the company's revenue comes from international sales, primarily in the US, Europe, Australia, and Southeast Asia [11]. IPO Fund Utilization - The company plans to raise 603 million yuan through its IPO, which will be allocated to the construction of a nutritional health raw material production base, expansion of production lines, establishment of a technology innovation center, and to supplement working capital [7][8].

Investment Rating - The report maintains a "Buy-A" investment rating for the company [4][6]. Core Views - The company achieved a total revenue of 19.19 billion yuan in 2024, representing a year-on-year increase of 12%, and a net profit attributable to shareholders of 3.35 billion yuan, up 22% year-on-year [1]. - The company's self-operated income doubled, while credit business income declined due to reduced interest income from stock pledge repurchase business [3]. - The asset management business shows significant advantages, and the progress in fund advisory services is notable, indicating potential long-term benefits from the wealth management market [4]. Business Performance Summary - **Brokerage**: The company had a net income of 2.5 billion yuan in brokerage services, down 10% year-on-year [1]. - **Investment Banking**: The company completed 4 equity financing projects totaling 1.33 billion yuan, ranking 8th in the industry for the number of projects [2]. - **Asset Management**: The total management scale of Dongzheng Asset Management reached 216.6 billion yuan, with 257 products managed [2]. - **Credit Business**: The net income from credit business decreased by 25% year-on-year, primarily due to reduced interest income from stock pledge repurchase [3]. - **Self-Operated Business**: The self-operated business net income increased by 106% year-on-year, driven by gains from other debt investments and trading financial assets [3]. Financial Forecast Summary - **Revenue Forecast**: Expected revenues for 2025, 2026, and 2027 are projected at 20.623 billion yuan, 22.966 billion yuan, and 25.099 billion yuan respectively [5][10]. - **Net Profit Forecast**: Projected net profits for the same years are 3.68 billion yuan, 4.187 billion yuan, and 4.672 billion yuan respectively [5][10]. - **Earnings Per Share (EPS)**: Expected EPS for 2025, 2026, and 2027 are 0.43 yuan, 0.49 yuan, and 0.55 yuan respectively [4][10].

一、说明会类型 本次业绩说明会以视频和网络互动形式召开，公司将针对2024年度经营成果及财务指标的具体情况与投 资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2025年4月11日（星期五）15:15-16:30 ●会议召开方式：视频和网络互动 ●会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） ●投资者可于2025年4月3日（星期四）至4月10日（星期四）16:00前登录上证路演中心网站首页点击"提 问预征集"栏目或通过公司邮箱ir@orientsec.com.cn进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 东方证券股份有限公司（以下简称"公司"）已于2025年3月29日发布公司2024年年度报告。为便于广大 投资者更全面深入地了解公司的经营成果和财务状况，公司计划于2025年4月11日1 ...